汉森制药(002412) - 2024 Q4 - 年度财报

Financial Performance - The company's operating revenue for 2024 was ¥1,004,469,462.29, representing a 5.12% increase compared to ¥955,530,797.42 in 2023[17]. - The net profit attributable to shareholders for 2024 was ¥220,244,409.11, up 7.43% from ¥205,014,883.78 in 2023[17]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥211,153,898.06, a 2.89% increase from ¥205,216,869.31 in 2023[17]. - The basic earnings per share for 2024 was ¥0.4377, reflecting a 7.44% increase from ¥0.4074 in 2023[17]. - The total assets at the end of 2024 were ¥2,547,234,247.32, a 9.02% increase from ¥2,336,488,623.93 at the end of 2023[17]. - The net assets attributable to shareholders at the end of 2024 were ¥2,203,382,060.15, up 12.24% from ¥1,963,028,938.67 at the end of 2023[17]. - The cash flow from operating activities for 2024 was ¥130,783,795.99, a decrease of 18.74% compared to ¥160,946,071.17 in 2023[17]. - The weighted average return on equity for 2024 was 10.57%, down from 11.54% in 2023[17]. - The company reported a total non-operating income of 9,090,511.05 in 2024, a significant recovery from a loss of 201,985.53 in 2023[23]. - Government subsidies recognized in the current period amounted to 6,122,286.14 in 2024, up from 4,028,779.66 in 2023[23]. Research and Development - The company plans to continue investing in R&D to enhance product development and expand its product portfolio, focusing on generics and innovative drugs[28]. - The product research and development saw the registration of Englitazone tablets 25mg and progress in clinical trials for Tianma Wake Brain[45]. - The company intends to increase R&D investment and accelerate new product development, aiming for deeper integration with research institutions and universities[71]. - The number of R&D personnel decreased by 9.68% to 196, with the proportion of R&D personnel in the total workforce dropping to 11.70%[58]. - Research and development expenses for 2024 were ¥39,322,290.36, a decrease of 11.5% from ¥44,479,163.31 in 2023[186]. Market Position and Strategy - The company has established itself as a leading player in the pharmaceutical manufacturing industry, recognized as a provincial-level enterprise technology center in Hunan[28]. - The company has exclusive production rights for four proprietary products and five unique dosage forms, enhancing its market position[28]. - The company’s main products include traditional Chinese medicine and chemical drugs, addressing various health conditions such as digestive and cardiovascular issues[30]. - The marketing strategy focuses on leveraging product strengths and optimizing channel management to enhance market presence and capture additional market share[41]. - The company has successfully participated in multiple centralized procurement projects, securing qualifications for various products, including "Si Mo Tang Oral Liquid" and "Ginkgo Leaf Capsules" in significant procurement initiatives[37]. Operational Efficiency - The company has established a comprehensive procurement management system, enhancing supplier management and reducing procurement costs through competitive bidding and strategic sourcing[34]. - The production model is market-oriented, ensuring sufficient supply while maintaining reasonable inventory levels, with a focus on lean production to improve efficiency and reduce costs[36]. - The company launched a lean marketing management upgrade project to enhance value creation and maintenance[44]. - The company initiated the second phase of lean production projects, focusing on data collection and evaluation analysis[45]. - The company emphasizes a collaborative approach among departments to improve marketing execution and enhance overall management capabilities[36]. Governance and Compliance - The company maintains an independent business system and operates independently from its controlling shareholders in all aspects, including personnel, assets, and finance[84]. - The company has established a transparent performance evaluation system for directors and senior management, ensuring clear incentives and penalties[82]. - The company has a dedicated internal audit department that supervises daily operations and major related transactions[82]. - The company emphasizes information disclosure and investor relations, ensuring timely and accurate communication with all investors[82]. - The company has a complete governance structure that complies with the requirements of the China Securities Regulatory Commission[79]. Environmental and Social Responsibility - The company emphasizes green production and has implemented measures to reduce carbon emissions, including water resource recycling and wastewater treatment[120]. - The company has increased investment in environmental protection technology upgrades, effectively reducing pollution emissions during production[123]. - The company made a donation of 30,000 yuan to support poverty alleviation and rural revitalization efforts in Yiyang City[124]. - The company provides a good working environment and various social insurances for employees, emphasizing talent development and safety training[122]. Shareholder Relations - The company has established a three-year shareholder return plan (2024-2026) to enhance its dividend decision-making and supervision mechanism[109]. - The company ensures that minority shareholders have the opportunity to express their opinions and that their legal rights are protected[110]. - The company held its annual general meeting with a participation rate of 43.86% on May 21, 2024, where nine resolutions were passed, including the 2023 Board of Directors' work report[85]. - The company has fulfilled all commitments made by its actual controllers, shareholders, and related parties during the reporting period[126]. Financial Management - The total pre-tax remuneration for the board of directors, supervisors, and senior management amounted to RMB 503.26 million[97]. - The company has a remuneration system that aligns with its operational performance and individual performance[95]. - The company has established a comprehensive internal control system in accordance with relevant laws and regulations[113]. - The internal control evaluation report indicates that the company maintained effective financial reporting internal controls as of December 31, 2024[117]. - The company has not reported any penalties from securities regulatory authorities for its directors and supervisors in the past three years[94].